We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $552M
1-Year Est. Return 551.78%
This Fund
S&P 500
This Quarter Est. Return
+22.56%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$552M
AUM Growth
+$7.32M
Cap. Flow
-$37.8M
Cap. Flow %
-6.85%
Top 10 Hldgs %
77.03%
Holding
24
New
4
Increased
10
Reduced
6
Closed
3

Top Buys

Rank Stock Value
1
CADL icon
Candel Therapeutics
CADL
+$15.8M
2
IRON icon
Disc Medicine
IRON
+$10.5M
3
IVVD icon
Invivyd
IVVD
+$5.9M
4
IMMX icon
Immix Biopharma
IMMX
+$5.1M
5
ZURA icon
Zura Bio
ZURA
+$4.47M

Top Sells

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$21.8M
2
OCUL icon
Ocular Therapeutix
OCUL
+$18.3M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$14.9M
4
DYN icon
Dyne Therapeutics
DYN
+$14.2M
5
ABVX
Abivax
ABVX
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%

No holdings matched the selected filter criteria.

Similar funds

TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
BT
Brandywine Trust Hockessin, Delaware $552M AUM 5.23% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.32% 1-Year Est. Return
IQI
Integrated Quantitative Investments Bellevue, Washington $551M AUM 45.27% 1-Year Est. Return
BCM
Bienville Capital Management New York $550M AUM 3.49% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $549M AUM 24.44% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Saturn V Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Saturn V Capital Management held 24 positions worth $552M, up 1.3% from $545M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Saturn V Capital Management withdrew a net $37.8M in Q1 2026, closing 3 positions and reducing 6 holdings. Its most notable exit was Ocular Therapeutix, an estimated $18.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Saturn V Capital Management opened a new position in Candel Therapeutics worth $14.2M.

  • Saturn V Capital Management's largest Q1 2026 buy was Candel Therapeutics: 2,896,588 shares worth $14.2M.
  • Saturn V Capital Management added most to Disc Medicine in Q1 2026, an estimated $10.5M increase.
  • Saturn V Capital Management's biggest Q1 2026 reduction was Cogent Biosciences, cutting an estimated $21.8M.
  • Saturn V Capital Management fully exited Ocular Therapeutix in Q1 2026, selling an estimated $18.3M.
  • Saturn V Capital Management's ten largest holdings make up 77% of its $552M portfolio in Q1 2026.
  • Saturn V Capital Management opened 4 new positions and closed 3 in Q1 2026.
  • Saturn V Capital Management's portfolio value rose 1.3% quarter-over-quarter to $552M.

Based on Saturn V Capital Management's 13F filing for Q1 2026, filed 15 May 2026.